Observation on the effect of telbivudine combined with adefovir dipivoxil and entecavir monotherapy in the treatment of decompensated hepatitis B cirrhosis
Objective To observe and compare the efficacy of telbivudine combined with adefovir dipivoxil and entecavir monotherapy in the treatment of decompensated hepatitis B cirrhosis. Methods 125 patients with decompensated hepatitis B cirrhosis selected in May 2015 to June 2016 were divided into control group (n=63) and observation group (n=62). The control group was treated with entecavir monotherapy, the observation group was treated with telbivudine combined with adefovir dipivoxil. The liver function indices and the conversion rate of HBV-DNA and HBeAg seroconversion in two groups were observed. Results There was no significant difference in ALT, ALB, TBil, PTA and Child-pugh scores after 12 months of treatment between the observation group and the control group.There was no significant difference in HBV-DNA negative rate and HBeAg serology conversion between the two groups at 3 months, 6 months and 12 months. Conclusion Telbivudine combined with adefovir dipivoxil and entecavir monotherapy in the treatment of decompensated hepatitis B cirrhosis have a significant effect, fewer side effects, clinical drug selection according to the actual situation of patients.
NETL
NSTL
万方数据
维普
